Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe fat and blood molecules to unlock new diabetes treatments

NCT ID NCT06955130

Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates how two molecules—glycerol from fat and lactate from the blood—are converted into glucose by the liver, especially in people with type 2 diabetes. Researchers will compare these processes in 48 adults with and without diabetes or obesity. Participants receive infusions of glycerol, lactate, and glucose along with glucagon, and blood samples are analyzed to track carbon flow. The goal is to identify new drug targets for lowering blood glucose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glycerol, Lactate, Glucose
What this could lead to
If successful, this research could point toward new drug targets that lower blood glucose more effectively in type 2 diabetes.
What could go wrong
This is an early-stage observational study with only 48 participants. It measures metabolic processes, not treatment outcomes, so direct benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for All Subjects 1. Age 40-70 years. 2. The subject is otherwise in general good health, based on medical history and physical examination. Inclusion Criteria for Metabolically Healthy Subjects without Obesity 1. No evidence of T2D or prediabetes as indicated by the American Diabetes Association (ADA), i.e., HbA1c \< 5.7%, fasting glucose \< 100 mg/dL, or use of glucose-lowering medications. 2. Body mass index (BMI) ≤ 24.9 kg/m2. Inclusion Criteria for Metabolically Healthy Subjects with Obesity 1. No evidence of T2D or prediabetes as per ADA criteria. 2. 30.0 ≤ BMI ≤ 45.0 kg/m2. Inclusion Criteria for T2D Subjects 1. Evidence of T2D as indicated by ADA criteria. 2. 6.5% ≤ HbA1c ≤ 8.0%. 3. 30.0 ≤ BMI ≤ 45.0 kg/m2. Exclusion Criteria for All Subjects 1. Chronic medical conditions that may affect glucose metabolism, including active malignancy, tobacco use, HIV infection, kidney failure, liver dysfunction, alcoholism, pancreatitis, active viral/bacterial infection, current pregnancy/lactation, anemia, severe cardiac or respiratory failure, and uncontrolled hyperlipidemia (total cholesterol ≥ 260 mg/dL or triglycerides ≥400 mg/dL). 2. Current medical therapy that affects glucose metabolism such as glucocorticoid, antipsychotic, or oral contraceptive pills. 3. Type 1 diabetes mellitus diagnosis and/or history of diabetic ketoacidosis. 4. Use of weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy Obesity Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.